Elite Pharmaceuticals Inc (ELTP)

[Sixman]

$ELTP once had potential, but that potential has been squandered by bad management and nonexistent execution. A few years ago, the two-bead technology had promise. The opioid epidemic was becoming better understood. As it's been litigated, it became clear, the two bead technology, as good as it may be, does not deter overdosing. This is true in the oral form, and in the FDA's mind it's true from a lack of BE due to inadequate Tmax.

The fact this data was never shared. The secrecy from management. This stock is DIW.

So many other opportunities in the pain management space. ELTP will be overrun.